demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
Kinase inhibitors
imatinib Aman

1 studies excluded by filtering options 0

6323 Roschewski, 2020 2990excludednot a RCTrisk of bias not avaialble